Introduction. One of the most common complications of diabetes, which leading to reduced life expectancy and disability, are lesions of peripheral arteries including the arteries of the lower extremities. About 7 % of population of Ukraine suffers from diabetes, 20 % of the costs for the treatment of patients with diabetes accounted for the treatment of lower limb lesions. The foregoing actualizes the problem of the treatment of patients with lower limb lesions and diabetes mellitus at the national level.

The aim of research is evaluation of combined medicine “Grandazol” efficacy in the treating purulo-necrotic lesions of lower extremities on the background of diabetic angiopathy.

Methods. The study was carried out from 2014 to 2016; 41 adult patients diagnosed with purulo-necrotic forms of diabetic foot, who were admitted to surgery department of a hospital, were enrolled in the study. Within 10 days of antibiotic therapy patients of the study group received 200 ml Grandazol (ornidazole 1000 mg and levofloxacin 500 mg), patients in the control group — ceftriaxone 1000 mg and metronidazole 1.500 mg per day intravenously. All patients underwent surgical treatment and a standard therapy. The effectiveness of antibiotic therapy was assessed by disk diffusion method, decrease in body temperature, signs of inflammation, and by the level of white blood cells and pain. Grandazol hepatotoxicity was estimated on NCIC-CTC grading system, recommendations of WHO and International union against cancer.

Results. In 100% of patients there was a high sensitivity of bacterial strains to Grandazol. Grandazol demonstrated a powerful anti-bacterial effect, and significantly excels in the decrease in temperature and pain (р<0.05). The study showed a Grandazol positive effect on necrotizing fasciitis with reducing the need for amputations. Grandazol administration within 10 days did not cause hepatotoxicity or other side effects.

Conclusions. Using Grandazol as a medicine of first choice for the treatment of purulo-necrotic forms of diabetic foot is safe and reasonable.